Abstract: The present disclosure discloses use of mesenchymal stem cells in preparation of a formulation for promoting fat transplantation, relating to the field of biotechnologies. The inventors found through research that compared with MSCs derived from somatic cells, MSCs derived from human pluripotent stem cells have more stable quality, are not affected by donor's physical quality, disease and treatment process, and can promote fat transplantation by enhancing tissue remodeling, angiogenesis and adipose cell survival and decreasing tissue fibrosis.